Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema.
The post BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal appeared first on MedCity News.
